The American Journal of Medicine
Volume 123, Issue 7 , Pages 638-645.e4 , July 2010

Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review

Poster was presented at the American College of Cardiology Annual Meeting 2009 in Orlando, Florida on March 29, 2009.

  • Isla M. Ogilvie, PhD

      Affiliations

    • BioMedCom Consultants Inc., Montréal, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Isla Ogilvie, PhD, BioMedCom Consultants Inc., 1405 TransCanada, Suite 310, Montréal, QC H9P2V9, Canada
    • ,
  • Nick Newton, PhD

      Affiliations

    • BioMedCom Consultants Inc., Montréal, Canada
    • ,
  • Sharon A. Welner, PhD

      Affiliations

    • BioMedCom Consultants Inc., Montréal, Canada
    • ,
  • Warren Cowell, MSc

      Affiliations

    • Global Health Economics and Reimbursement, Bayer HealthCare, Uxbridge, England
    • ,
  • Gregory Y.H. Lip, MD

      Affiliations

    • Haemostasis Thrombosis & Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

References 

  1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375
  2. Murphy NF, Simpson CR, Jhund PS, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart. 2007;93:606–612
  3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–125
  4. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008;117:1255–1260
  5. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–953
  6. Guize L, Thomas F, Bean K, et al. Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up [French]. Bull Acad Natl Med. 2007;191(4-5):791–803
  7. Friberg J, Scharling H, Gadsboll N, et al. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol. 2004;94:889–894
  8. Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51:810–815
  9. The Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69:546–554
  10. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99:295–304
  11. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–e354
  12. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):429S–456S
  13. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;113:e873–e923
  14. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 36—Atrial Fibrillation: The Management of Atrial Fibrillation. London: National Institute for Health and Clinical Excellence; 2006;
  15. Hankey GJ. Non-valvular atrial fibrillation and stroke prevention (National Blood Pressure Advisory Committee of the National Heart Foundation). Med J Aust. 2001;174:234–239
  16. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;1–11
  17. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870
  18. Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?. Stroke. 2007;38:2459–2463
  19. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988
  20. Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials (The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators). Stroke. 1999;30:1223–1229
  21. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049–1056
  22. Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018–3026
  23. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001;104:2118–2150
  24. Dewilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006;92:1064–1070
  25. Frykman V, Beerman B, Ryden L, et al. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J. 2001;22(20):1954–1959
  26. Kalra L, Yu G, Perez I, et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ. 2000;320(7244):1236–1239
  27. Bravata DM, Rosenbeck K, Kancir S, Brass LM. The use of warfarin in veterans with atrial fibrillation. BMC Cardiovasc Disord. 2004;4:18
  28. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927–934
  29. Gandolfo C, Balestrino M, Burrone A, et al. Stroke due to atrial fibrillation and the attitude to prescribing anticoagulant prevention in Italy: a prospective study of a consecutive stroke population admitted to a comprehensive stroke unit. J Neurol. 2008;255:796–802
  30. Humphries KH, Jackevicius C, Gong Y, et al. Population rates of hospitalization for atrial fibrillation/flutter in Canada. Can J Cardiol. 2004;20:869–876
  31. Rowan SB, Bailey DN, Bublitz CE, et al. Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database. J Am Coll Cardiol. 2007;49:1561–1565
  32. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice?. Arch Intern Med. 2001;161:1443–1447
  33. Leckey R, Aguilar EG, Phillips SJ. Atrial fibrillation and the use of warfarin in patients admitted to an acute stroke unit. Can J Cardiol. 2000;16(4):481–485
  34. Ageno W, Ambrosini F, Nardo B, et al. Atrial fibrillation and antithrombotic treatment in Italian hospitalized patients: a prospective, observational study. J Thromb Thrombolysis. 2001;12:225–230
  35. Meiltz A, Zimmermann M, Urban P, Bloch A Association of Cardiologists of the Canton of Geneva. Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace. 2008;10:674–680
  36. Suzuki S, Yamashita T, Ohtsuka T, et al. Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. Circ J. 2008;72:914–920
  37. Srivastava A, Hudson M, Hamoud I, et al. Examining warfarin underutilization rates in patients with atrial fibrillation: detailed chart review essential to capture contraindications to warfarin therapy. Thromb J. 2008;6:6
  38. Partington SL, Abid S, Teo K, et al. Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: the appropriate use and barriers to oral anticoagulant therapy. Thromb Res. 2007;120:663–669
  39. Boulanger L, Kim J, Friedman M, et al. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract. 2006;60:258–264
  40. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37:1070–1074
  41. Inoue H, Nozawa T, Hirai T, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J. 2006;70:651–656
  42. Brophy MT, Snyder KE, Gaehde S, et al. Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc. 2004;52:1151–1156
  43. Filippi A, Bettoncelli G, Zaninelli A. Detected atrial fibrillation in north Italy: rates, calculated stroke risk and proportion of patients receiving thrombo-prophylaxis. Fam Pract. 2000;17:337–339
  44. Bo S, Valpreda S, Scaglione L, et al. Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study. BMC Public Health. 2007;7:203
  45. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly (The Framingham Study). Arch Intern Med. 1987;147:1561–1564
  46. Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167:246–252
  47. Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol. 2006;97:538–543
  48. Gattellari M, Worthington J, Zwar N, et al. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke. 2008;39:227–230
  49. Anderson N, Fuller R, Dudley N. ‘Rules of thumb’ or reflective practice? (Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation). QJM. 2007;100:263–269
  50. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019–1026
  51. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897–902
  52. Darkow T, Vanderplas AM, Lew KH, et al. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin. 2005;21:1583–1594
  53. Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100:599–607
  54. Go AS. Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care. 2004;10(3 Suppl):S58–S65
  55. McNamara RL, Tamariz LJ, Segal JB, et al. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003;139:1018–1033
  56. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation (The Atrial Fibrillation Investigators). Stroke. 2009;40:1410–1416
  57. Hansen ML, Gadsboll N, Gislason GH, et al. Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. Europace. 2008;10:395–402
  58. Leoo T, Lindgren A, Petersson J, et al. Risk factors and treatment at recurrent stroke onset: results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study. Cerebrovasc Dis. 2008;25:254–260
  59. Fornari LS, Calderaro D, Nassar IB, et al. Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent. J Thromb Thrombolysis. 2007;23:65–71
  60. Andersen KK, Olsen TS. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22,179 patients with ischemic stroke. Stroke. 2007;38:259–263
  61. Burgess C, Ingham T, Woodbridge M, et al. The use of antithrombotics in patients presenting with stroke and atrial fibrillation. Ther Clin Risk Manag. 2007;3:491–498
  62. Deplanque D, Leys D, Parnetti L, et al. Secondary prevention of stroke in patients with atrial fibrillation: factors influencing the prescription of oral anticoagulation at discharge. Cerebrovasc Dis. 2006;21:372–379
  63. Burton C, Isles C, Norrie J, et al. The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study. Br J Gen Pract. 2006;56:697–702
  64. Touze E, Cambou JP, Ferrieres J, et al. Antithrombotic management after an ischemic stroke in French primary care practice: results from three pooled cross-sectional studies. Cerebrovasc Dis. 2005;20:78–84
  65. de Lusignan S, van Vlymen J, Hague N, et al. Preventing stroke in people with atrial fibrillation: a cross-sectional study. J Public Health (Oxf). 2005;27:85–92
  66. Bordin P, Mazzone C, Pandullo C, et al. Morbidity and mortality in 229 elderly patients with nonrheumatic atrial fibrillation (A five-year follow-up). Ital Heart J. 2003;4:537–543
  67. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA. 2003;290:2685–2692
  68. Evans A, Perez I, Yu G, et al. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?. Stroke. 2001;32:2828–2832
  69. Howard PA, Ellerbeck EF, Engelman KK, et al. Warfarin for stroke prevention in octogenarians with atrial fibrillation. Am J Geriatr Cardiol. 2001;10:139–144
  70. Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke. 2000;31:1217–1222
  71. Tomita F, Kohya T, Sakurai M, et al. Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan. Jpn Circ J. 2000;64:653–658
  72. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31:822–827
  73. Caro JJ, Flegel KM, Orejuela ME, et al. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. CMAJ. 1999;161:493–497
  74. Deplanque D, Corea F, Arquizan C, et al. Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? (SAFE I Study Investigators). Heart. 1999;82:563–569
  75. White RH, McBurnie MA, Manolio T, et al. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am J Med. 1999;106:165–171
  76. Brass LM, Krumholz HM, Scinto JD, et al. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med. 1998;158:2093–2100
  77. Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke. 1997;28:2382–2389
  78. Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med. 1997;157:978–984

 Funding: This study was funded by Bayer Healthcare, UK.

 Conflict of Interest: Dr. Gregory Y.H. Lip has acted as a consultant for Bayer Healthcare, AstraZeneca, Astellas, and Boehringer; and Warren Cowell is employed by Bayer Healthcare, UK. The other authors have no conflict of interest.

 Authorship: All authors had full access to data for this study and participated in writing and review of the manuscript.

PII: S0002-9343(10)00254-8

doi: 10.1016/j.amjmed.2009.11.025

The American Journal of Medicine
Volume 123, Issue 7 , Pages 638-645.e4 , July 2010

Article Tools

* Image Usage & Resolution